Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis
Tiffany Y Loh,1 Jennifer L Hsiao,2 Vivian Y Shi1 1University of Arizona, Division of Dermatology, Tucson, AZ, USA; 2University of California Los Angeles, Division of Dermatology, Los Angeles, CA, USACorrespondence: Vivian Y ShiDivision of Dermatology, University of Arizona, 7165 N Pima Canyon Drive,...
Main Authors: | Loh TY, Hsiao JL, Shi VY |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-02-01
|
Series: | Journal of Asthma and Allergy |
Subjects: | |
Online Access: | https://www.dovepress.com/therapeutic-potential-of-lebrikizumab-in-the-treatment-of-atopic-derma-peer-reviewed-article-JAA |
Similar Items
-
Managing Atopic Dermatitis with Lebrikizumab – The Evidence to Date
by: Labib A, et al.
Published: (2022-06-01) -
The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
by: Bader Bashrahil, et al.
Published: (2023-01-01) -
Incidence of conjunctivitis adverse event in patients treated with biologics for atopic dermatitis: A systematic review and meta-analysis
by: Rose Alraddadi, MD, et al.
Published: (2023-12-01) -
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
by: Amy S. Paller, et al.
Published: (2023-06-01) -
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
by: Kim Rand, et al.
Published: (2023-10-01)